
During a live event, Pedro Barata, MD, MSc, and participating oncologists discussed how efficacy, tolerability, and clinical evidence inform subsequent-line treatment selection for metastatic clear cell renal cell carcinoma.
Intermediate-Risk Newly Diagnosed Metastatic Renal Cell Carcinoma
Case Scenario: A 52-year old male with mRCC
February 2018